Clinical trials: Schizo-Affective Type of Psychosis
Schizophrenia, Schizoaffective Disorder
Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders
The investigators propose to recruit individuals with schizophrenia who are symptomatically stable and already taking medications to participate in this study.
- Trial name
- NCT01519557
- Testing
- DAR-100A
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia
Smokers with schizophrenia have more difficulties quitting smoking than smokers without a mental disorder. Varenicline (Champix) is a new stop smoking medication with a unique mechanism of action.
- Trial name
- NCT01093365
- Testing
- Varenicline
- Where
- Canada
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia and Schizoaffective Disorder, Bipolar Disorder (BD)
Survey on the Reproductive and Child-Rearing Situations of Patients With Severe Mental Disorders
Severe mental disorders represent a major public health concern, imposing substantial disease burden and adversely affecting multiple dimensions of patients' lives, while also creating intergenerational impacts on their offspring…
- Trial name
- NCT07005245
- Where
- China
- Volunteers
- 77,145 people
- Sponsor
- Peking University
Schizophrenia, Schizoaffective Disorder
Remediation of Auditory Recognition in Schizophrenia With tDCS
The purpose of this study is to determine whether transcranial direct current stimulation (tDCS), when combined with different forms of computer based training, improves the ability to discriminate small differences between…
- Trial name
- NCT02869334
- Testing
- Active Transcranial direct current stimulation (tDCS), Auditory Remediation, Control computer activities
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document the long-term safety and tolerability of risperidone, formulated as a long-acting injectable, in the treatment of patients with schizophrenia or schizoaffective disorder; in addition, to…
- Trial name
- NCT00210691
- Testing
- Risperidone
- Volunteers
- 273 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Cognitive Remediation for Coordinated Specialty Care
Cognitive remediation (CR) is an evidence-based behavioral skills intervention that targets the cognitive processes underlying functioning in everyday life.
- Trial name
- NCT03930251
- Testing
- Clinic-Based Cognitive Remediation, Partial-Remote Cognitive Remediation
- Where
- 9 sites in United States
- Volunteers
- 117 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Video as a Tool to Improve Insight in Schizophrenia
The deficit of awareness of pathology (or insight) is a common symptom in patients with schizophrenia and has a negative impact on the prognosis of the disease.
- Trial name
- VideoInsight (NCT02664129)
- Testing
- Video self-observation, Non Self video observation
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Montpellier
Schizophrenia, Schizoaffective Disorder
How Can Rehospitalisations of Patients With Schizophrenia be Avoided? A Comparison Between Different Compliance Programs
Participation in one of the three interventions psychoeducation by professionals, psychoeducation by peer-moderators, or video-education can reduce the rehospitalisation rate of patients with schizophrenia compared to a control…
- Trial name
- NCT00514423
- Testing
- Psychoeducation by professonals, Psychoeducation by peer-moderators, Video-education
- Where
- Germany
- Volunteers
- 896 people
- Sponsor
- Technical University of Munich
Schizophrenia, Schizoaffective Disorder
D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions
This study is a placebo-controlled 12 week trial of DCS augmentation of once-weekly CBT sessions in 60 schizophrenia subjects with antipsychotic-resistant delusions.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- NCT01981759
- Testing
- D-Cycloserine, Cognitive Behavioral Therapy
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- NYU Langone Health
Schizophrenia, Diabetes Mellitus
A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess and compare how risperidone and olanzapine, two antipsychotic medications, affect the regulation of glucose (sugar) in the body.
- Trial name
- NCT00236379
- Testing
- Olanzapine, Risperidone
- Volunteers
- 59 people
- Sponsor
- Janssen, LP
Schizophrenia, Schizoaffective Disorder
Characterizing Response to Antipsychotics in Schizophrenia
The goal of this research project is to develop MRI-based biomarkers to identify patients with schizophrenia who are most likely to benefit from first-line antipsychotic or clozapine treatment.
- Trial name
- NCT06159322
- Testing
- Olanzapine, Clozapine
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- The Royal Ottawa Mental Health Centre
SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder
Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways
This study investigates the ability of transcranial direct current stimulation (tDCS) applied over the motion processing area of the brain (area MT) to improve face emotion recognition (FER) ability.
- Trial name
- ButtomVP (NCT07469384)
- Testing
- transcranial direct current stimulation
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Bipolar I Disorder, Schizoaffective Disorder
Open Label Extension Study of NCT06221852
This is a 12-week open-label extension study for participants completing study NCT06221852.
- Conditions
- Bipolar I Disorder, Schizoaffective Disorder, Psychosis
- Trial name
- NCT06558201
- Testing
- Ketogenic diet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mclean Hospital
Chronic Schizophrenia, Schizoaffective Disorder
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or…
- Trial name
- NCT01450514
- Testing
- Pipamperone
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- PharmaNeuroBoost N.V.
Schizophrenia, Schizoaffective Disorder
An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia
The purpose of this study is to evaluate the long-term efficacy and safety of a long-acting injectable formulation of risperidone (an antipsychotic medication) and its influence on quality of life, in participants with…
- Trial name
- NCT00269919
- Testing
- Risperidone Long-Acting Injectable (RLAI)
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenic Disorders
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and…
- Trial name
- NCT00660595
- Testing
- Quetiapine, Risperidone
- Where
- 4 sites in Finland
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Schizophrenia
L-Theanine in the Management of Schizophrenia
The aim of the proposed study is to investigate the efficacy and safety of add-on gamma-glutamylethylamide (L-theanine) versus a placebo for antipsychotic treatment for 8 weeks in a randomized, double-blind, parallel group study…
- Trial name
- NCT00372151
- Testing
- L-Theanine
- Where
- 2 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Sha'ar Menashe Mental Health Center
Schizophenia Disorder, Schizoaffective Disorder
Exercise and Olanzapine-samidorphan
This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic…
- Conditions
- Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
- Trial name
- NCT06740890
- Testing
- Olanzapine-samidorphan + exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- New York State Psychiatric Institute
Schizoaffective Disorder, Schizophrenia
Genetic Study of Schizophrenia
This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness.
- Trial name
- NCT00001486
- Where
- United States
- Volunteers
- 4,914 people
- Sponsor
- National Institute of Mental Health (NIMH)
Psychotic Disorders, Schizophrenia
Examining the Efficacy of a Virtual Reality Cognitive Remediation Program for People Living With Psychosis
Individuals living with a psychotic disorder often experience changes to their thinking and social skills that can lead to challenges with work, school, relationships and living independently.
- Conditions
- Psychotic Disorders, Schizophrenia, Schizo Affective Disorder
- Trial name
- NCT05973110
- Testing
- Cognitive Remediation, Active Control
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- The Royal Ottawa Mental Health Centre